publication venue for
- <p>Stated Preferences for Attributes of a <em>CYP2C19</em> Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario</p>. Volume 12:167-175. 2020
- <p>A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients</p>. Volume 11:477-486. 2019
- <p>Electronic referral systems in health care: a scoping review</p>. Volume 11:325-333. 2019
- A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. Volume 10:821-854. 2018
- Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Volume 10:127-137. 2018
- Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada. Volume 10:201-212. 2018
- Economic analysis of pharmacist-administered influenza vaccines in Ontario, Canada. Volume 10:655-663. 2018
- Procedure costs associated with the use of Harmonic devices compared to conventional techniques in various surgeries: a systematic review and meta-analysis. Volume 10:399-412. 2018
- Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. Volume 9:65-73. 2017
- Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. 7:213-213. 2015
- Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. 6:49-49. 2014
- Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. 4:349-349. 2012
- Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. 4:287-287. 2012
- Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada. 4:21-21. 2012
- Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. 3:89-89. 2011